Table 4 Overview of literature
Author | Stage | Type of radiation treatment | Total dose | Treatment response | PFS | OS |
|---|---|---|---|---|---|---|
Lindahl et al.[16] | T1 5.7% | TSEBT | High-dose (30 Gy) n = 25 | High-dose: CR 68% | 9 months median | n. a. |
T2 40% | Low-dose (4 Gy) n = 10 | Low-dose:CR 10% | ||||
T3 48.6% | ||||||
T4 5.7% | ||||||
Navi et al.[17] | T2 57% | TSEBT (+/- HN2) | 36 Gy (range 30-40 Gy) | T2: CCR 75% | T2: 8.5 years | T2: 10.9 years |
T3 43% | T3: CCR 47% | T3: 2.9 years | T3: 4.7 years | |||
Kamstrup et al.[16] | T2 n = 6 | TSEBT | 10 Gy | OR 90% | median response duration 5.2 months | n. a. |
T3 n = 2 | CR 30% | |||||
T4 n = 2 | ||||||
Chinn et al.[18] | T2 n = 55 | TSEBT (+/- HN2) | Mostly 36 Gy | T2: CR 76% | Freedom from recurrence at 1 year 41% | T2: 10.7 years |
T3 n = 27 | T3: CR 44% | T3: 3.6 years | ||||
This Analysis | IIB n = 4 | TSEBT | Median 29 Gy | OR 92% | 5 months | 10 months |
III n = 1 | CCR 52% | |||||
IVA n = 10 | ||||||
IVB n = 7 |